A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102

Annals of Oncology

Volumn 20, Issue 6, 2009, Pages 1074-1079

  Philips, George K ^a   Halabi, S ^b   Sanford, B L ^b   Bajorin, D ^c   Small, E J ^d  

^a UNIVERSITY OF VERMONT   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; EGFR; Gefitinib; Transitional cell carcinoma; Urothelial

Indexed keywords

CISPLATIN; CREATININE; GEFITINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ELECTROCORTICOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEARING LOSS; HEMATURIA; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; KIDNEY PELVIS CARCINOMA; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELENA; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; URETER CARCINOMA; URETHRA CARCINOMA; UROGENITAL TRACT CANCER; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; UROLOGIC NEOPLASMS;

EID: 66149084012     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn749     Document Type: Article

References (28)

1. Jemal A, Seigel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17(10): 3173-3181.
3. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23(21): 4602-4608.
4. Soto PH, Cavina R, Latteri F et al. Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study. Ann Oncol 2002; 13(7): 1080-1086.
5. Als AB, Sengelov L, von der Maase H. Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? Acta Oncol 2008; 47: 110-119.
6. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003; 46 (Suppl): S85-S104.
7. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69(6): 1120-1125.
8. Neal DE, Sharples L, Smith K et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65(7): 1619-1625.
9. Ravery V, Colombel M, Popov Z et al. Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer. Br J Cancer 1995; 71(1): 196-200.
10. Turkeri LN, Erton ML, Cevik I, Akdas A. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 1998; 51(4): 645-649.
11. Bue P, Wester K, Sjostrom A et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998; 76(2): 189-193.
12. Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6(5): 2053-2063.
13. Sirotnak FM, Zakowski MF, Miller VA et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6(12): 4885-4892.
14. Dominguez-Escrig JL, Kelly JD, Neal DE et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004; 10(14): 4874-4884.
15. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5(2): 257-265.
16. Inoue K, Salton JW, Perrotte P et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874-4884.
17. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-784.
18. Gandhi V, Plunkett W, Du M et al. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 2002; 20(3): 665-673.
19. Tempero M, Plunkett W, Ruiz VH et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21(18): 3402-3408.
20. Philips GK, Halabi S, Sanford BL et al. A phase II trial of cisplatin (C), fixed dose rate gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. BJU Int 2007; 101: 20-25.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer: National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
22. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23(1): 18-20.
23. Blehm KN, Spiess PE, Bondaruk JE et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy. Clin Cancer Res 2006; 12: 4671-4677.
24. Kassouf W, Dinney CP, Brown G et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res. 2005; 65: 10524-10535.
25. Jacobs MA, Wotkowicz C, Baumgart ED et al. Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. J Urol 2007; 178: 1510-1514.
26. Petrylak DP, Faulkner JR, Van Veldhuizen PJ et al. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 2005; 22: 403.
27. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23(25): 5892-5899.
28. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2): 123-132.